The Latest Cardiac and Vascular News
BRISBANE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the fourth quarter and full year ended December 31, 2019. “MyoKardia achieved significant progress in 2019, advancing our pipeline and regaining global rights to our entire portfolio. There were important data readouts across our clinical programs, including one-year […]
Achieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM Significant Reductions in Biomarkers of Cardiac Stress Observed in Patients on Treatment vs. Placebo Data Support Advancement of Mavacamten in Non-obstructive HCM; Regulatory Update Anticipated in the First Half of 2020 Phase 2 Study of Mavacamten Targeting Subgroup of Patients with Diastolic […]
Mavacamten’s Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten’s Favorable Impact on Cardiac Structure Conference Call Today at 8:30 a.m. ET (5:30 a.m. PT); Data Presentation at American Heart Association Scientific Sessions on Monday, November 18, 2019 SOUTH SAN […]
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the quarter ended September 30, 2019. “As we look across the milestones recently achieved and those just ahead, we see steady progress on our near- and long-term corporate objectives. We are forging a position of disease-area […]
Planned Study Will Assess Effect of Mavacamten on the Need for SRT Among HCM Patients Referred for Invasive Procedures SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy (SRT). The study will be conducted at […]
Durability of Mavacamten’s Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers Maintained, Indicative of Potential Improvements in Cardiac Function and Favorable Impact on Long-Term Disease Burden PARIS and SOUTH SAN FRANCISCO, Calif., Aug. 31, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) […]
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy (HCM). HCM is a progressive disease in which the excessive contraction of the […]
Pre-Application Letters of Intent are Due September 13 for the 2019-2020 Funding Cycle SOUTH SAN FRANCISCO, Calif., Aug. 15, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. today announced the launch of the 2nd Annual MyoSeeds™ Research Grants Program, an initiative to support original, independent research in the biology and underlying mechanisms of cardiomyopathies and precision heart disease treatment. […]
Announces Last Patient to be Enrolled in EXPLORER-HCM Phase 3 during the Week of August 12th; Topline Data Accelerated to 2nd Quarter 2020 Topline Phase 2 Clinical Data from MAVERICK-HCM and MYK-491 on Track for Fourth Quarter 2019 Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., […]
SOUTH SAN FRANCISCO, Calif., July 18, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today announced updates related to its hypertrophic cardiomyopathy (HCM) treatment portfolio, including lead therapeutic candidate, mavacamten. Patient screening has closed for the Phase 3 EXPLORER-HCM registrational clinical study to assess the effect of mavacamten in treating patients with obstructive hypertrophic cardiomyopathy […]
